IGB offers integrated solutions for Cell & Gene Therapy (CGT) workflows, supporting the complete journey from cell isolation to final analytical quality control and cryopreservation.
These workflows encompass critical steps such as isolation, activation, genetic engineering, expansion, characterization, and preservation of therapeutic cells for translational research and clinical manufacturing applications.
Leveraging technologies from leading partners including Thermo Fisher Scientific, Takara Bio, Bio-Techne, and Repligen, these solutions enable streamlined, scalable, and reproducible CGT processes across research and GMP environments.
The workflow supports key processes such as cell isolation and enrichment, washing and buffer exchange, activation and expansion, gene editing and viral transduction, viral vector processing, analytical characterization, and protein analysis.
Applications include advanced therapeutic areas such as CAR-T, TCR-T, and NK cell therapies, as well as stem cell research, viral vector development, CRISPR-based gene editing, and translational to GMP-scale manufacturing.
Features:
End-to-end workflow integration from cell isolation to analytical QC and storage
GMP-compatible solutions supporting translational and clinical manufacturing workflows
Closed-system cell processing for washing, concentration, and buffer exchange
Advanced cell engineering support including CRISPR, lentiviral transduction, and mRNA workflows
Viral vector processing solutions including tangential flow filtration (TFF) and purification
High-end analytical characterization using flow cytometry, imaging, qPCR, and protein analysis
Scalable solutions from research-scale discovery to bioprocess manufacturing
Multi-vendor technology integration combining leading platforms and expertise
